Women receiving care for breast cancer have significantly impaired cardio-pulmonary function that can persist for years after they have completed treatment, according to a study led by scientists at Duke University Medical ...
May 23, 2012
0
0
Chemotherapy is a commonly used regimen for cancer treatment, but it is also a double-edged sword. While the drugs are highly effective at killing cancer cells, they are also notorious for killing healthy cells in the body. ...
Jan 24, 2023
0
51
Researchers have identified why some advanced estrogen receptor (ER) positive breast cancers become resistant to hormone therapy, and have identified drugs currently in development that could keep disease stable for longer ...
Feb 7, 2024
0
0
(HealthDay)—The use of robotically assisted surgical devices for breast removal and other cancer-related surgeries is not approved by the U.S. Food and Drug Administration because there is no proof of its safety or effectiveness ...
Mar 1, 2019
0
3
Hair loss can be devastating for women, but the condition can also signal additional health problems.
Mar 17, 2023
0
8
Cardiovascular disease is the leading cause of mortality in breast cancer survivors. A new study out of the Baker Heart and Diabetes Institute has found that exercise training three to four times per week protects against ...
Nov 8, 2022
0
21
Brain metastases are common secondary complications of other types of cancer, particularly lung, breast and skin cancer. The body's own immune response in the brain is rendered powerless in the fight against these metastases ...
Sep 25, 2012
0
0
New research is shedding light on how leukaemia cells can survive cancer treatment, suggesting new possibilities for stopping them in their tracks.
Oct 17, 2016
0
56
A team of researchers from the MRC Weatherall Institute of Molecular Medicine at Oxford University has developed a new technique that allows scientists to reliably track genetic errors in individual cancer cells, and find ...
Feb 12, 2019
1
11
All patients in the Phase I / II clinical trial of glofitamab had Diffuse Large B-Cell Lymphoma (DLBCL) and their cancer had relapsed or was no longer responding to conventional treatments, including CAR T-cell therapy.
Dec 12, 2022
0
47
